Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2021-10-09 Director's Dealing
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2021-10-09 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a Note Purchase Agreement, detailing the terms of a financing arrangement including secured notes, interest rates, covenants, and conditions. This is a clear update on the company's capital raising and financing activities. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a proxy, legal proceeding, or governance report. The detailed description of the Note Purchase Agreement and related financing terms fits the Capital/Financing Update category. The document length (over 11,000 characters) and detailed content confirm it is the actual announcement, not just a brief notice or report publication announcement.
2021-10-04 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 9, 2021. It announces the issuance of a press release with positive topline data from a clinical study and mentions a conference call and webcast presentation to discuss these results. The document includes references to a press release and a slide presentation as exhibits. The content focuses on disclosure of new data and an upcoming investor presentation rather than detailed financial statements or comprehensive analysis. The document length is 4247 characters, which is relatively short and primarily serves as an announcement of the press release and presentation rather than the full presentation or report itself. Therefore, this fits best as an Investor Presentation (IP) filing type, as it includes a slide presentation for investors focusing on financials, strategy, and market position related to the clinical data announcement.
2021-09-09 English
10-Q
Interim / Quarterly Report Q2 2021
2021-08-16 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text specifically mentions "Item 2.02 Results of Operations and Financial Conditions" and states that the company announced its financial results for the quarter ended June 30, 2021. It also references a press release as Exhibit 99.1 containing the full text of the announcement. The document is 3734 characters long, which is relatively short and primarily serves as a vehicle to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2021-08-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-07-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.